After years of chasing growth, behavioral health founders are being told the next round depends on evidence, not reach.
Behavioral health funding has consolidated hard around a smaller group of startups, and the survivors are increasingly the ones that can show their care actually worked, not just that patients showed up.
A 50% funding drop, then consolidation
Mental health tech funding fell roughly 50%, from a $5.5B peak in 2021 to about $1.4B in 2024, before consolidating around a smaller group of scaled players including Lyra Health, Spring Health and Headway.
Greenspace Health was named G2's Best Platform for Measurement-Based Care and Outcomes Tracking in 2026, a category that barely existed as a distinct evaluation criterion a few years earlier. A survey of 21 behavioral health organisation leaders found consensus that 2026 marks a pivot away from a race to scale and toward clinical credibility and measurable accountability.
AI-native entrants are testing a different angle on the same proof problem: Slingshot AI raised $93M in 2025 to build a model purpose-built for psychology, part of a broader push toward conversational support, while the FDA's 2024 clearance of Rejoyn, the first prescription digital therapeutic for major depressive disorder, set an early regulatory marker for how much clinical evidence this category will eventually need to clear.
A market moving from "access to a therapist" toward "proof the therapy worked" is the same arc now playing out in women's health, described earlier in this issue, suggesting this is a broader 2026 pattern rather than a behavioral-health-specific one.
The standard is converging across categories
Payers and investors are converging on the same standard across categories: evidence that treatment produced a measurable change, not simply that a patient accessed care.
That is a harder bar to clear than utilisation metrics, and it is actively reshaping which startups can raise their next round, regardless of how strong their patient volume numbers look on their own. A platform with declining new-patient growth but strong measured outcomes is, in this market, a better funding story than one with the reverse.
Who treats measurement as a feature, not a checkbox
Watch measurement-based care shift from a clinical best practice into a baseline commercial requirement for any behavioral health startup raising capital in the second half of 2026.
Startups that treat it as a compliance checkbox rather than a genuine product feature are likely to fall further behind Lyra, Spring Health and Headway, not catch up to them, while AI-native entrants like Slingshot will face their own, separate test of whether conversational support tools can clear the same clinical evidence bar.
